ChiCTR2100053409 版本V1.2 版本创建时间2022/09/27 03:25:57 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100053409 

最近更新日期:

Date of Last Refreshed on:

2022-05-17 11:38:13 

注册时间:

Date of Registration:

2021-11-20 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于出生队列研究PCOS辅助生殖子代代谢综合征的发病风险及分子机制

Public title:

To study the risk and molecular mechanism of metabolic syndrome in PCOS assisted progeny based on birth cohort

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于出生队列研究PCOS辅助生殖子代代谢综合征的发病风险及分子机制

Scientific title:

To study the risk and molecular mechanism of metabolic syndrome in PCOS assisted progeny based on birth cohort

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

姜雯雯 

研究负责人:

刘光华 

Applicant:

JIang Wenwen 

Study leader:

Liu Guanghua 

申请注册联系人电话:

Applicant telephone:

+86 13600830574

研究负责人电话:

Study leader's telephone:

+86 591 87279505

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

360464638@qq.com

研究负责人电子邮件:

Study leader's E-mail:

fjfy_xrcx@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

福建省妇幼保健院

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

福建省福州市鼓楼区道山路18号

研究负责人通讯地址:

福建省福州市鼓楼区道山路18号

Applicant address:

18 Daoshan Road, Gulou District, Fuzhou, Fujian

Study leader's address:

18 Daoshan Road, Gulou District, Fuzhou, Fujian

申请注册联系人邮政编码:

Applicant postcode:

350001

研究负责人邮政编码:

Study leader's postcode:

350001

申请人所在单位:

福建省妇幼保健院

Applicant's institution:

Fujian Maternal and Child Health Hospital

研究负责人所在单位:

福建省妇幼保健院

Affiliation of the Leader:

Fujian Maternal and Child Health Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020YJ188

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

福建省妇幼保健院伦理委员会

Name of the ethic committee:

Ethics Committee of Fujian Maternal and Child Health Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2020-11-10 00:00:00

伦理委员会联系人:

张伯秋

Contact Name of the ethic committee:

Zhang Boqiu

伦理委员会联系地址:

福建省福州市鼓楼区道山路18号

Contact Address of the ethic committee:

18 Daoshan Road, Gulou District, Fuzhou, Fujian

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

福建省妇幼保健院

Primary sponsor:

Fujian Maternal and Child Health Hospital

研究实施负责(组长)单位地址:

福建省福州市鼓楼区道山路18号

Primary sponsor's address:

18 Daoshan Road, Gulou District, Fuzhou, Fujian

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

福建

市(区县):

福州

Country:

China

Province:

Fujian

City:

Fuzhou

单位(医院):

福建省妇幼保健院

具体地址:

鼓楼区道山路18号

Institution
hospital:

Fujian Maternal and Child Health Hospital

Address:

18 Daoshan Road, Gulou District

经费或物资来源:

闽财指〔2020〕467 号

Source(s) of funding:

Fujian Provincial Health Special Subsidy Fund in 2020 (2020) No. 467

Target disease:

Polycystic ovarian syndrome

Target disease code:

研究类型:

病因学/相关因素研究

Study type:

Cause/Relative factors study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

探究PCOS子代代谢综合征的发病风险及可能的分子机制。  

Objectives of Study:

To explore the risk and possible molecular mechanism of metabolic syndrome in offspring of PCOS.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.按照2018年多囊卵巢综合征中国诊疗指南诊断的PCOS患者;
2.年龄≤35 ;
3.IVF方案皆为拮抗剂方案。

Inclusion criteria

1. PCOS patients diagnosed according to the 2018 Chinese Guidelines for the Diagnosis and Treatment of Polycystic ovary Syndrome;
2. <=35 years old;
3.All IVF protocols were antagonist protocols.

排除标准:

其他内分泌疾病,如库欣综合征、甲状腺功能障碍、高泌乳素血症等。

Exclusion criteria:

Other endocrine diseases, such as Cushing's syndrome, thyroid dysfunction, hyperprolactinemia, etc.

研究实施时间:

Study execute time:

From 2020-09-01 00:00:00 To 2026-08-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-12-01 00:00:00 To 2026-11-30 00:00:00  

干预措施:

Interventions:

组别:

PCOS组

样本量:

300

Group:

Group PCOS

Sample size:

干预措施:

干预措施代码:

Intervention:

NO

Intervention code:

组别:

非PCOS组

样本量:

300

Group:

Group without PCOS

Sample size:

干预措施:

干预措施代码:

Intervention:

NO

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

福建 

市(区县):

福州 

Country:

China 

Province:

Fujian 

City:

Fuzhou 

单位(医院):

福建省妇幼保健院 

单位级别:

三级甲等 

Institution
hospital:

Fujian Maternal and Child Health Hospital

Level of the institution:

Teritary A

测量指标:

Outcomes:

指标中文名:

空腹血糖

指标类型:

主要指标

Outcome:

fasting blood-glucose

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脂质代谢

指标类型:

主要指标

Outcome:

lipid metabolism

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

子代出生体重

指标类型:

次要指标

Outcome:

Offspring birth weight

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

子代出生身长

指标类型:

次要指标

Outcome:

Offspring birth height

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

子代头围

指标类型:

次要指标

Outcome:

Offspring head circumference

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

新生儿并发症

指标类型:

次要指标

Outcome:

Neonatal complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

母体血清

组织:

Sample Name:

Maternal serum

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

子代血清

组织:

Sample Name:

offspring serum

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

母体卵泡液

组织:

卵泡组织

Sample Name:

Maternal follicular Fluid

Tissue:

Follicle tissue

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 35 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

No

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

no

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF表单和电子采集管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF and EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-11-20 19:40:48